FindTrial
Sign In

High-Dose Rosuvastatin Preloading for Enhanced Outcomes in STEMI Patients Undergoing Primary PCI

Efficacy Of High-Dose Rosuvastatin Preloading Before Primary Percutaneous Coronary Intervention In Patients Suffering From St-Elevation Myocardial Infarction

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06924684
Acronym
HEROS-PCI
Enrollment
66
Registered
2025-04-11
Start date
2024-12-02
Completion date
2025-07-02
Last updated
2025-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST Elevation (STEMI) Myocardial Infarction

Brief summary

To compare the efficacy of high dose rosuvastatin preloading vs placebo before primary PCI in terms of MACE at 30 days

Interventions

DRUGStatin monotherapy (rosuvastatin or atorvastatin)

Tab Rosuvastatin 40mg (weight) at presentation. Tab Rosuvastatin 20mg at night for 30 days.

DRUGPlacebo

Placebo caspule

Sponsors

Punjab Institute of Cardology
CollaboratorOTHER
Sheikh Zayed Federal Postgraduate Medical Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-75 years Patients undergoing primary angiography

Exclusion criteria

* Hemodynamically unstable patients. History or clinical evidence of any co-morbidities. Taking any medications regularly even statins.

Design outcomes

Primary

MeasureTime frame
Incidence of MACE30 days
In-Hospital mortality30 days

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026